GLP-1 and HRT Interaction: What Happens When You Combine Semaglutide or Tirzepatide with Hormone Therapy

What the labels say about combining them

The Wegovy drug interactions section is short. It covers insulin and insulin secretagogues such as sulfonylureas, where the concern is hypoglycemia, and oral medicines in general, because Wegovy delays gastric emptying [1]. Estrogen and progestogen products are not among the medicines it names [1]. The Wegovy contraindications are a personal or family history of medullary thyroid carcinoma or MEN 2 and a prior serious hypersensitivity reaction, not hormone therapy [1].

Wegovy is the weight-management semaglutide; Ozempic and Rybelsus are labeled for type 2 diabetes [1][5][6]. For tirzepatide, Zepbound covers weight and sleep apnea and Mounjaro covers type 2 diabetes [2][7].

Tirzepatide's label addresses hormones in one specific place: oral contraceptives. It advises women using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase [2]. Foundayo (orforglipron), a different oral GLP-1 drug, carries similar advice for 30 days after starting and after each dose escalation, and its label adds that hormonal contraceptives not administered orally should not be affected [8].

Does delayed gastric emptying affect estrogen or progesterone?

Wegovy's label states the mechanism plainly: it delays gastric emptying and thereby has the potential to impact the absorption of oral medicines, and it suggests increased clinical or laboratory monitoring for medicines with a narrow therapeutic index or that require monitoring [1]. The same label also notes that in clinical pharmacology trials with semaglutide 1 mg once weekly by injection, semaglutide did not affect the absorption of orally administered medicines [1]. In a drug interaction study with the semaglutide tablet, levothyroxine exposure rose 33% [1].

The closest labeled data to HRT are contraceptive steroids: a semaglutide tablet interaction study found no clinically significant change in ethinyl estradiol or levonorgestrel [1]. Those are the hormones used in the pill, not the estradiol and progesterone used in menopausal therapy.

Route matters. The gastric-emptying language in the labels is about swallowed medicines [1]. An estradiol patch, gel or spray and a vaginal ring, cream or tablet are not taken by mouth.

Estrogen products have their own interaction list

The Premarin label says estrogens are partly metabolized by CYP3A4, so inducers such as St John's wort, phenobarbital, carbamazepine and rifampin may lower plasma estrogen concentrations, while inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may raise them [3]. Duavee (conjugated estrogens with bazedoxifene) gives a concrete example: itraconazole raised bazedoxifene exposure by 40% and, to a lesser extent, conjugated estrogen exposure (9% for total estrone, 5% for total equilin) [9].

Those are the interactions the estrogen labels themselves flag. They involve a liver enzyme, CYP3A4, which is a different mechanism from the gastric-emptying note on the GLP-1 side [3][1].

HRT is not contraception

You can get pregnant during perimenopause even if you skip periods [10]. Premarin's labeled uses are moderate to severe vasomotor symptoms, vulvar and vaginal atrophy, hypoestrogenism from hypogonadism, castration or primary ovarian failure, palliative use in selected cancers, and prevention of postmenopausal osteoporosis; contraception is not among them, and the label says Premarin is not indicated for use during pregnancy [3]. The tirzepatide and orforglipron advice above is about oral contraceptives, which is a separate product from HRT [2][8].

Weight, menopause and the scale

A Cochrane review of 22 randomized trials (searches to 1998) found no significant weight change versus non-users for unopposed estrogen (+0.66 kg, 95% CI -0.62 to 1.93) or estrogen plus progestogen (-0.47 kg, -1.63 to 0.69) [4]. A review of the literature concluded that weight gain per se cannot be attributed to the menopause transition, although the hormonal change is associated with more total and abdominal fat that estrogen therapy may partly prevent, with further studies needed [11]. Weight loss is not a labeled use of Premarin [3].

What the transition does change is body composition. In the SWAN cohort, the rate of fat gain doubled at the start of the menopause transition and lean mass declined, continuing until about 2 years after the final menstrual period; total weight climbed steadily before menopause with no acceleration at the transition, then flattened [12].

For comparison, the main GLP-1 weight trials: STEP 1 enrolled 1,961 adults without diabetes; at 68 weeks, average weight loss was 14.9% with semaglutide and 2.4% with placebo [13]. SURMOUNT-1 enrolled 2,539 adults across tirzepatide and placebo groups; average weight loss at 72 weeks was 20.9% with the 15 mg tirzepatide dose versus 3.1% with placebo [14]. SURMOUNT-5 enrolled 751 adults across tirzepatide and semaglutide groups; average weight loss at 72 weeks was 20.2% with tirzepatide versus 13.7% with semaglutide [15]. Stopping matters too: in STEP 4, adults who switched to placebo after a 20-week semaglutide run-in regained 6.9% of body weight over 48 weeks while those who continued lost a further 7.9% [16].

What the Wegovy label says to watch for

The Wegovy label lists warnings for acute pancreatitis, acute gallbladder disease, acute kidney injury from volume depletion, severe gastrointestinal reactions, and resting heart rate increases of 1 to 4 beats per minute. It says Wegovy is not recommended in people with severe gastroparesis, and it says to discontinue if pancreatitis is suspected [1].

In the Wegovy weight-management trials, nausea occurred in 44% versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11%; 6.8% versus 3.2% stopped treatment because of adverse reactions, and hair loss was reported by 3% versus 1% [1].

On pregnancy, the weight-management labels say to discontinue when pregnancy is recognized, and Wegovy's label says to stop at least 2 months before a planned pregnancy because of its long half-life [1].